The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
A consensus has formed based on epidemiological studies and clinical trials that intervention to reduce low density lipoprotein cholesterol (LDL-C) will reduce cardiovascular disease (CVD) events. This has progressively reduced the thresholds for intervention and targets for treatment. Whist statins...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-05-01
|
| Series: | Therapeutic Advances in Chronic Disease |
| Online Access: | https://doi.org/10.1177/2040622320924569 |
| _version_ | 1818339227940683776 |
|---|---|
| author | Eun Ji Kim Anthony S. Wierzbicki |
| author_facet | Eun Ji Kim Anthony S. Wierzbicki |
| author_sort | Eun Ji Kim |
| collection | DOAJ |
| description | A consensus has formed based on epidemiological studies and clinical trials that intervention to reduce low density lipoprotein cholesterol (LDL-C) will reduce cardiovascular disease (CVD) events. This has progressively reduced the thresholds for intervention and targets for treatment. Whist statins are sufficient for many people in primary prevention, they only partially achieve the newer targets of secondary prevention for established CVD. Increasing use of statins has highlighted that 1–2% cannot tolerate these drugs. Other cholesterol-lowering drugs such as ezetimibe add to the benefits of statins but have limited efficacy. The discovery of activating mutations in proprotein convertase subtilisin kexin-9 (PCSK9) as a cause of familial hypercholesterolaemia while inactivating mutations lower LDL-C led to the idea to develop PCSK9 inhibitors as drugs. This article reviews the history of lipid-lowering therapies, the discovery of PCSK9 and the development of PCSK9 inhibitors. It reviews the key trials of the current antibody-based drugs and how these have influenced new guidelines. It also reviews the controversy caused by their cost and the increasing application of health economics to determine the optimum strategy for implementation of novel therapeutic pathways and surveys other options for targeting PCSK9 as well as other LDL-C lowering compounds in late development. |
| first_indexed | 2024-12-13T15:23:40Z |
| format | Article |
| id | doaj.art-806fa9680b684e228145e11ddb072984 |
| institution | Directory Open Access Journal |
| issn | 2040-6231 |
| language | English |
| last_indexed | 2024-12-13T15:23:40Z |
| publishDate | 2020-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Chronic Disease |
| spelling | doaj.art-806fa9680b684e228145e11ddb0729842022-12-21T23:40:27ZengSAGE PublishingTherapeutic Advances in Chronic Disease2040-62312020-05-011110.1177/2040622320924569The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular diseaseEun Ji KimAnthony S. WierzbickiA consensus has formed based on epidemiological studies and clinical trials that intervention to reduce low density lipoprotein cholesterol (LDL-C) will reduce cardiovascular disease (CVD) events. This has progressively reduced the thresholds for intervention and targets for treatment. Whist statins are sufficient for many people in primary prevention, they only partially achieve the newer targets of secondary prevention for established CVD. Increasing use of statins has highlighted that 1–2% cannot tolerate these drugs. Other cholesterol-lowering drugs such as ezetimibe add to the benefits of statins but have limited efficacy. The discovery of activating mutations in proprotein convertase subtilisin kexin-9 (PCSK9) as a cause of familial hypercholesterolaemia while inactivating mutations lower LDL-C led to the idea to develop PCSK9 inhibitors as drugs. This article reviews the history of lipid-lowering therapies, the discovery of PCSK9 and the development of PCSK9 inhibitors. It reviews the key trials of the current antibody-based drugs and how these have influenced new guidelines. It also reviews the controversy caused by their cost and the increasing application of health economics to determine the optimum strategy for implementation of novel therapeutic pathways and surveys other options for targeting PCSK9 as well as other LDL-C lowering compounds in late development.https://doi.org/10.1177/2040622320924569 |
| spellingShingle | Eun Ji Kim Anthony S. Wierzbicki The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease Therapeutic Advances in Chronic Disease |
| title | The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease |
| title_full | The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease |
| title_fullStr | The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease |
| title_full_unstemmed | The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease |
| title_short | The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease |
| title_sort | history of proprotein convertase subtilisin kexin 9 inhibitors and their role in the treatment of cardiovascular disease |
| url | https://doi.org/10.1177/2040622320924569 |
| work_keys_str_mv | AT eunjikim thehistoryofproproteinconvertasesubtilisinkexin9inhibitorsandtheirroleinthetreatmentofcardiovasculardisease AT anthonyswierzbicki thehistoryofproproteinconvertasesubtilisinkexin9inhibitorsandtheirroleinthetreatmentofcardiovasculardisease AT eunjikim historyofproproteinconvertasesubtilisinkexin9inhibitorsandtheirroleinthetreatmentofcardiovasculardisease AT anthonyswierzbicki historyofproproteinconvertasesubtilisinkexin9inhibitorsandtheirroleinthetreatmentofcardiovasculardisease |